Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion, Inc.

Biomea Fusion is a clinical-stage biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers.  Biomea Fusion's lead investigational compound, BMF-219, is a covalent menin inhibitor.  The company also develops BMF-500, a covalent FLT3 inhibitor.

COM:BIOMEAFUSION

Biomea Fusion

Last Close

6.38

22/11 21:00

Market Cap

170.74M

Beta: -

Volume Today

490.54K

Avg: -

Financials Not Available